Skip to main content
profileAnalyst coverage5 yr. financialspremium researchdividendsadv. chartsearningsoptionsprice history

Altimmune, Inc. News

Cramer's Mad Money Recap: PepsiCo, JPMorgan Chase, Goldman Sachs

Jim Cramer says investors need to watch out for next week's economic data, COVID news and bank earnings. He's got your game plan.

Medicinova Jumps on Phase 2 Progress With Alcohol-Abuse Drug

Medicinova's clinical trials found that its ibudilast reduced the odds of heavy drinking over time by 45% relative to a placebo.

Nanox Higher on Application to FDA for Medical Imaging System

Nanox shares climbed after the medical-imaging-tech company applied to the FDA for clearance of a system that produces scans of human body parts.

Altimmune Higher After Phase 1 Progress With Obesity Drug

Altimmune jumped after it reported progress from its Phase 1 trial of ALT-801, a drug for obesity and liver disease.

Altimmune's Covid Vaccine Candidate Placed on Clinical Hold

Altimmune says it doesn't expect 'a significant impact on the overall clinical development timeline.'

Breaking News

The Good Times Are Over for Startups

Sequoia Capital and Y Combinator have told startups that cutting costs is a priority.

Elon Musk Throws Dogecoin a Lifeline

Elon Musk will soon allow Dogecoin to purchase SpaceX merchandise.

Disney Fans Angry, Excited About New Guardians of the Galaxy Ride

The theme park company has opened Guardians of the Galaxy: Cosmic Rewind and not everyone is happy despite the ride getting wonderful reviews.

Aurora Cannabis Slashing Weed Capacity in Profitability Push

Aurora is slashing its production capacity as it builds a runway toward positive Ebitda a year from now.